First patient dosed in Phase 1/Phase 2 LION-CS101 trial of AB-1003 in August 2023, with enrollment continuing Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...
The findings are supported by rigorous biochemical assays and state-of-the-art microscopy methods, although the evidence, while overall solid, is only partially developed, and some points could be ...
Netflix flexes documentary muscle with eight projects in the running for an Oscar, but National Geo, others have strong ...
Explore the role and challenges of AAV characterization, the significance of capsid filling, and the best methods to enhance ...
The e-commerce’s grocery store concept is joining ... a nonprofit with a mission to find a cure for Duchenne muscular dystrophy. The event marked a new milestone for the shootout, as Ryan ...
Based on a small trial with positive muscle performance data, Regenxbio is expected to pursue approval of its gene therapy ...
28, 2024 — Using state-of-the-art technology, researchers have identified ... New Gene Therapy Approach Shows Promise for Duchenne Muscular Dystrophy July 24, 2024 — Researchers have made ...
Gene therapy can effectively treat various diseases, but for some debilitating conditions like muscular dystrophies there is ...
Mouse model reveals liver involvement in muscular dystrophy. ScienceDaily . Retrieved November 15, 2024 from www.sciencedaily.com / releases / 2024 / 10 / 241024145510.htm ...
In muscular dystrophy type 1, mutated DNA begets toxic RNA that alter liver function, including susceptibility to fatty liver disease and hypersensitivity to drugs.
The Muscular Dystrophy Association (MDA) proudly highlights National Family Caregivers Awareness Month this November. MDA's month-long campaign emphasizes the essential role caregivers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback